Kite Expands Cell Therapy Manufacturing Operations in Maryland
Supreme Court Denied Juno’s Appeal Request in Juno vs. Kite Case
Kite Receives U.S. Food and Drug Administration (FDA) Orphan Drug Designation for KITE-222 for Acute Myeloid Leukemia
Kite Launches CAR T-cell Therapy Operations in Brazil, Singapore and Saudi Arabia
Kite Announces U.S. FDA Clearance of Investigational New Drug Application for Kite-363, a Dual-Targeting CAR T-Cell Therapy Candidate for Large B-Cell Lymphoma
Kite’s Yescarta® (Axicabtagene Ciloleucel) Car T-Cell Therapy Now Widely Available and Publicly Funded for Patients in Australia with Four Types of Aggressive Non-Hodgkin Lymphoma
Kite Announces U.S. FDA Clearance of Investigational
Some content on this site is not intended for people outside the United States.
